Stocks and Investing
Stocks and Investing
Tue, March 19, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Mon, March 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $11 on, Mar 18th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $11 on, Mar 18th, 2024.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Colin Bristow of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Wednesday, February 21st, 2024
These are the ratings of the 2 analyists that currently disagree with Raghuram
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $7 on, Thursday, March 14th, 2024
- Geoff Meacham of "B of A Securities" Maintained at Strong Buy with Decreased Target to $7 on, Wednesday, March 13th, 2024
Contributing Sources